Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2024
Event: Entry into a Material Definitive Agreement (Amended and Restated At-The-Market Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a capital raising mechanism rather than operational financial results.
- Maximum Offering Amount: Up to $75,000,000 in aggregate offering price.
- Commission Rate: 3.0% of gross sales proceeds paid to sales agents.
- Sales Agents: RBC Capital Markets, LLC and BTIG, LLC.
- Underlying Registration: Form S-3 (File No. 333-279036), declared effective August 7, 2024.
Material Changes
The Company entered into an Amended and Restated At-The-Market Sales Agreement on August 9, 2024. This agreement supersedes or updates previous arrangements, allowing the Company to offer and sell shares of its common stock from time to time at its sole discretion. The Company is not obligated to sell any shares, and sales will depend on market conditions and capital needs.
Guidance, Outlook, and Risks
Management Commentary: The Company retains full discretion over whether to sell shares under the agreement. Sales agents are not obligated to purchase shares on a principal basis but will use commercially reasonable efforts to sell shares based on Company instructions regarding price, time, or size limits.
Risks and Contingencies:
- Sales are subject to customary closing conditions and limitations set forth in the Sales Agreement.
- The Company must reimburse sales agents for certain specified expenses upon entering the agreement and on a quarterly basis.
- Offers are subject to state securities laws and registration requirements.
Investor Verification Checklist
- Verify the current cash position and burn rate to assess the immediate necessity of utilizing the $75 million ATM facility.
- Review the full text of the Amended and Restated Sales Agreement (Exhibit 1.1) for specific limitations on the volume of shares that can be sold daily or weekly.
- Monitor future filings for actual sales activity and the resulting dilution to existing shareholders.
- Confirm the impact of the 3.0% commission and reimbursement expenses on net proceeds.